Compare CURX & PAVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CURX | PAVM |
|---|---|---|
| Founded | 2018 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.6M | 7.1M |
| IPO Year | 2025 | 2016 |
| Metric | CURX | PAVM |
|---|---|---|
| Price | $0.28 | $10.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $510.00 |
| AVG Volume (30 Days) | 2.7M | ★ 3.0M |
| Earning Date | 09-09-2025 | 03-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $29,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $450.56 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.61 | $6.00 |
| 52 Week High | $8.60 | $28.44 |
| Indicator | CURX | PAVM |
|---|---|---|
| Relative Strength Index (RSI) | 32.40 | 56.23 |
| Support Level | $0.27 | $10.24 |
| Resistance Level | $0.31 | $11.34 |
| Average True Range (ATR) | 0.03 | 1.34 |
| MACD | -0.00 | -0.22 |
| Stochastic Oscillator | 11.45 | 40.36 |
Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout.
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, esocheck, and the Veris Cancer Care Platform.